Japan Pharmas Enlist Government In Fight Against Fake Drugs
This article was originally published in PharmAsia News
Executive SummaryJapanese drug makers, including subsidiaries of multinational corporations, are in the forefront of an effort to crack down on the spread of counterfeit drugs in the country. Some of the major makers count success in getting Japanese authorities to block the trade in counterfeit erectile dysfunction drugs in the past two years. The effort led to 123,000 fake Pfizer Viagra (sildenafil citrate) pills alone to be seized. A Japanese professor notes the spread of fake drugs could cause a loss of credibility for genuine medicines. (Click here for more
You may also be interested in...
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January 2020.
Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.